Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

Registrieren

MCRB Seres Therapeutics Inc

1,11

0,04 (3,74%)

06 Jun 2024 - Geschlossen

Verzögert um 15 Minuten

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

Seres Therapeutics (NASDAQ:MCRB)
Historical Stock Chart
Von Mai 2024 bis Jun 2024

Click Here for more Seres Therapeutics Charts.

Seres Therapeutics (NASDAQ:MCRB)
Historical Stock Chart
Von Jun 2023 bis Jun 2024

Click Here for more Seres Therapeutics Charts.

News Seres Therapeutics Inc

Form 4 - Statement of changes in beneficial ownership of securities
Samstag 18 Mai 2024 (3 Wochen vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Samstag 18 Mai 2024 (3 Wochen vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Samstag 18 Mai 2024 (3 Wochen vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Samstag 18 Mai 2024 (3 Wochen vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Samstag 18 Mai 2024 (3 Wochen vor) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Mittwoch 8 Mai 2024 (4 Wochen vor) • Edgar (US Regulatory)

Form 8-K - Current report
Mittwoch 8 Mai 2024 (4 Wochen vor) • Edgar (US Regulatory)

Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
Mittwoch 8 Mai 2024 (4 Wochen vor) • Business Wire

Form 8-K - Current report
Dienstag 7 Mai 2024 (4 Wochen vor) • Edgar (US Regulatory)

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Montag 6 Mai 2024 (1 Monat vor) • Business Wire

Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024
Montag 6 Mai 2024 (1 Monat vor) • Business Wire

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT
Dienstag 9 April 2024 (2 Monate vor) • Business Wire

Weitere Seres Therapeutics Inc News-Artikel

NLBNPIT1WSQ3 20240920 29...

Mitsu Hc Cap.24

Societe Generale Effekten

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen